Liposome Kinetics in Infarcted Canine Myocardium

Caride, Vicente J.; Twickler, Jeff; Zaret, Barry L.

doi:10.1097/00005344-198411000-00003

Cited by 15 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early studies of liposomes in myocardial infarction used dual-radionuclide radiolabelled liposomes with 99m Tc to follow the lipid components and entrapped 125 I-HSA or 125 I-polyvinylpyrrolidone in the aqueous compartment [104], or 3 H-cholesterol and 99m Tc-DTPA respectively [282]. This strategy helped assess the integrity of the liposomes in the circulation.…”

Section: Applications Of Radiolabelled Liposomesmentioning

confidence: 99%

Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine

Man

Gawne

Rosales

2019

Advanced Drug Delivery Reviews

120

View full text Add to dashboard Cite

The integration of nuclear imaging with nanomedicine is a powerful tool for efficient development and clinical translation of liposomal drug delivery systems. Furthermore, it may allow highly efficient imaging-guided personalised treatments. In this article, we critically review methods available for radiolabelling liposomes. We discuss the influence that the radiolabelling methods can have on their biodistribution and highlight the often-overlooked possibility of misinterpretation of results due to decomposition in vivo. We stress the need for knowing the biodistribution/pharmacokinetics of both the radiolabelled liposomal components and free radionuclides in order to confidently evaluate the images, as they often share excretion pathways with intact liposomes (e.g. phospholipids, metallic radionuclides) and even show significant tumour uptake by themselves (e.g. some radionuclides). Finally, we describe preclinical and clinical studies using radiolabelled liposomes and discuss their impact in supporting liposomal drug development and clinical translation in several diseases, including personalised nanomedicine approaches.

show abstract

Section: Applications Of Radiolabelled Liposomesmentioning

confidence: 99%

Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine

Man

Gawne

Rosales

2019

Advanced Drug Delivery Reviews

120

View full text Add to dashboard Cite

show abstract

“…Doxorubicin liposomes reach steady state faster and with fewer doses due to intensified localization to targeted organs 30 . Theoretically, liposomes are highly effective carriers after MI, achieving higher drug concentration at sites of cardiac injury due to increased vascular permeability 27 , 31 , 32 . Indeed, liposomal delivery formulations are effective drug delivery strategies for phagocyte-targeted therapy, producing lower immunogenic reaction, higher biocompatibility and specificity, and greater drug stability 33 .…”

Section: Introductionmentioning

confidence: 99%

Liposomal delivery of azithromycin enhances its immunotherapeutic efficacy and reduces toxicity in myocardial infarction

Al-Darraji

Donahue

Tripathi

et al. 2020

Sci Rep

View full text Add to dashboard Cite

A growing body of evidence shows that altering the inflammatory response by alternative macrophage polarization is protective against complications related to acute myocardial infarction (MI). We have previously shown that oral azithromycin (AZM), initiated prior to MI, reduces inflammation and its negative sequelae on the myocardium. Here, we investigated the immunomodulatory role of a liposomal AZM formulation (L-AZM) in a clinically relevant model to enhance its therapeutic potency and avoid off-target effects. L-AZM (40 or 10 mg/kg, IV) was administered immediately post-MI and compared to free AZM (F-AZM). L-AZM reduced cardiac toxicity and associated mortality by 50% in mice. We observed a significant shift favoring reparatory/anti-inflammatory macrophages with L-AZM formulation. L-AZM use resulted in a remarkable decrease in cardiac inflammatory neutrophils and the infiltration of inflammatory monocytes. Immune cell modulation was associated with the downregulation of pro-inflammatory genes and the upregulation of anti-inflammatory genes. The immunomodulatory effects of L-AZM were associated with a reduction in cardiac cell death and scar size as well as enhanced angiogenesis. Overall, L-AZM use enhanced cardiac recovery and survival after MI. Importantly, L-AZM was protective from F-AZM cardiac off-target effects. We demonstrate that the liposomal formulation of AZM enhances the drug’s efficacy and safety in an animal model of acute myocardial injury. This is the first study to establish the immunomodulatory properties of liposomal AZM formulations. Our findings strongly support clinical trials using L-AZM as a novel and clinically relevant therapeutic target to improve cardiac recovery and reduce heart failure post-MI in humans.

show abstract